Jefferies Group Equities Analysts Reduce Earnings Estimates for Immune Design Corp. (IMDZ)
Immune Design Corp. (NASDAQ:IMDZ) – Stock analysts at Jefferies Group reduced their Q3 2017 EPS estimates for Immune Design Corp. in a research note issued on Thursday. Jefferies Group analyst M. Raycroft now forecasts that the biotechnology company will earn ($0.64) per share for the quarter, down from their prior forecast of ($0.62). Jefferies Group has a “Buy” rating and a $18.00 price objective on the stock. Jefferies Group also issued estimates for Immune Design Corp.’s Q4 2017 earnings at ($0.66) EPS, FY2017 earnings at ($2.37) EPS, FY2018 earnings at ($2.43) EPS, FY2019 earnings at ($0.17) EPS and FY2020 earnings at ($1.25) EPS.
Other research analysts have also issued reports about the company. BidaskClub lowered Immune Design Corp. from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Zacks Investment Research upgraded Immune Design Corp. from a “hold” rating to a “buy” rating and set a $11.00 price objective on the stock in a research report on Tuesday, July 18th. Cowen and Company reiterated a “buy” rating on shares of Immune Design Corp. in a research report on Tuesday, June 6th. Finally, ValuEngine upgraded Immune Design Corp. from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $14.50.
Shares of Immune Design Corp. (NASDAQ IMDZ) opened at 10.475 on Monday. The company’s market cap is $268.36 million. Immune Design Corp. has a 1-year low of $4.50 and a 1-year high of $13.05. The stock has a 50 day moving average price of $9.47 and a 200-day moving average price of $7.03.
Immune Design Corp. (NASDAQ:IMDZ) last posted its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.54) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.65) by $0.11. Immune Design Corp. had a negative return on equity of 59.14% and a negative net margin of 324.33%. The company had revenue of $0.73 million for the quarter, compared to the consensus estimate of $1.50 million.
In other news, Director Lewis W. Coleman acquired 12,000 shares of the firm’s stock in a transaction on Tuesday, July 11th. The shares were purchased at an average cost of $9.05 per share, for a total transaction of $108,600.00. Following the transaction, the director now owns 40,000 shares of the company’s stock, valued at $362,000. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Wayne Gombotz sold 10,000 shares of the stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $11.43, for a total value of $114,300.00. Following the completion of the transaction, the insider now owns 33,054 shares in the company, valued at $377,807.22. The disclosure for this sale can be found here. Insiders acquired a total of 30,000 shares of company stock worth $272,760 over the last quarter. Corporate insiders own 42.90% of the company’s stock.
A number of hedge funds and other institutional investors have recently made changes to their positions in IMDZ. Bank of America Corp DE raised its position in shares of Immune Design Corp. by 123.3% in the first quarter. Bank of America Corp DE now owns 15,246 shares of the biotechnology company’s stock worth $104,000 after buying an additional 8,418 shares during the last quarter. State of Wisconsin Investment Board purchased a new position in shares of Immune Design Corp. during the second quarter worth approximately $117,000. Trexquant Investment LP purchased a new position in shares of Immune Design Corp. during the first quarter worth approximately $183,000. Rhumbline Advisers raised its position in shares of Immune Design Corp. by 53.9% in the second quarter. Rhumbline Advisers now owns 19,694 shares of the biotechnology company’s stock worth $192,000 after buying an additional 6,896 shares during the last quarter. Finally, TIAA CREF Investment Management LLC raised its position in shares of Immune Design Corp. by 18.9% in the first quarter. TIAA CREF Investment Management LLC now owns 45,574 shares of the biotechnology company’s stock worth $310,000 after buying an additional 7,236 shares during the last quarter. Hedge funds and other institutional investors own 50.60% of the company’s stock.
Immune Design Corp. Company Profile
Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.
Receive News & Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related companies with MarketBeat.com's FREE daily email newsletter.